Foghorn Therapeutics Inc.

FHTXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1822462

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$22.6M	$34.2M	$19.2M	$1.3M	$430.0K
Research and Development Expense	$94.5M	$109.7M	$105.6M	$80.3M	$57.7M
Operating Expenses	$125.3M	$142.1M	$136.4M	$102.1M	$69.0M
Operating Income (Loss)	-$102.7M	-$107.9M	-$117.1M	-$100.7M	-$68.5M
Interest Expense	—	—	—	—	$979.0K
Nonoperating Income (Expense)	$16.1M	$13.7M	$8.3M	-$586.0K	-$269.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	-$94.2M	-$108.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$284.0M	$285.9M	$404.9M	$519.8M	$255.6M
Assets, Current	$249.6M	$240.2M	$351.4M	$459.6M	$190.7M
Cash and Cash Equivalents, at Carrying Value	$55.5M	$80.3M	$52.2M	$101.1M	$92.8M
Liabilities	$329.5M	$363.1M	$404.8M	$422.9M	$109.4M
Liabilities, Current	$67.0M	$58.4M	$55.2M	$48.7M	$18.8M
Accounts Payable, Current	$3.8M	$6.3M	$5.4M	$3.8M	$3.7M
Stockholders' Equity Attributable to Parent	-$77.2M	$112.0K	$96.9M	$146.2M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$100.4M	-$118.1M	$193.6M	-$50.3M	-$31.3M
Net Cash Provided by (Used in) Investing Activities	-$29.9M	$144.4M	-$244.3M	$36.2M	-$108.9M
Net Cash Provided by (Used in) Financing Activities	$105.4M	$1.8M	$1.8M	$22.4M	$217.5M
Payments to Acquire Property, Plant, and Equipment	$906.0K	$1.2M	$1.2M	$3.3M	$16.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)